Battelle, one of the world’s largest independent, non-profit R&D organisations, focuses its contract research efforts on three areas: health, national security & environment. Its involvement in drug delivery goes back to the 1990s – main areas of focus are: injectors, patch pumps and inhalation.
Battelle is one of the world’s largest independent, non-profit research and development organisations. Its founding mission is to translate scientific discovery and technology advances into societal benefits, and it focuses its contract research efforts on three main areas: health, national security and environment.
Within its health offering, drug delivery is a major pillar, as is human-centric design. Its involvement in drug delivery goes back to the early 1990s and its three predominant areas of focus are: injectors, patch pumps and inhalation technology.
Among the organisation’s accomplishments within drug delivery are: one of the first pen injectors on the market; the first digital device commercially launched; design, engineering and launch support for the most successful subcutaneous platform in the history of drug delivery technology; and full or partial involvement in the development, refinement and commercialisation of more than 30 unique delivery systems across a range of modalities
Battelle’s Advanced Drug Delivery Initiative (ADDI) responds to unmet market needs with the next generation of innovations in drug delivery. The ADDI is a family of concepts built on Battelle technologies and form factors.
Battelle was founded in 1929 and is now a US$8.2 billion (£6.3 billion) enterprise.